Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1128/AAC.01101-20 http://scihub22266oqcxt.onion/10.1128/AAC.01101-20 32631826!7449177!32631826     free     free     free       Antimicrob+Agents+Chemother 2020 ; 64 (9): ä Nephropedia Template TP {{tp|p=32631826|t=2020. Clinical Trials of Repurposed Antivirals for SARS-CoV-2 |pdf=|usr=}}{{32631826}} gab.com Text Clinical Trials of Repurposed Antivirals for SARS-CoV-2 JO: Antimicrob Agents Chemother http://www.kidney.de/pget.php?&tw=1&pmid=32631826 #FOAvip The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has prompted the repurposing of drugs on the basis of promising in vitro and therapeutic results with other human coronavirus diseases, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). These repurposed drugs have mainly included remdesivir, favipiravir, lopinavir-ritonavir, ribavirin, interferons, and hydroxychloroquine. Unfortunately, the first open-label, randomized, controlled trials are showing poor efficacy of these repurposed drugs. These results highlight the necessity of identifying and characterizing specific and potent SARS-CoV-2 antivirals. Twit Text FOAVip Clinical Trials of Repurposed Antivirals for SARS-CoV-2 ????Antimicrob Agents Chemother http://www.kidney.de/pget.php?&tw=1&pmid=32631826 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32631826 #FOAvip English Wikipedia <ref>{{Cite pmid|32631826}}</ref> Clinical Trials of Repurposed Antivirals for SARS-CoV-2 #MMPMID32631826 Martinez MA Antimicrob Agents Chemother 2020[Aug]; 64 (9): ä PMID32631826show ga The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has prompted the repurposing of drugs on the basis of promising in vitro and therapeutic results with other human coronavirus diseases, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). These repurposed drugs have mainly included remdesivir, favipiravir, lopinavir-ritonavir, ribavirin, interferons, and hydroxychloroquine. Unfortunately, the first open-label, randomized, controlled trials are showing poor efficacy of these repurposed drugs. These results highlight the necessity of identifying and characterizing specific and potent SARS-CoV-2 antivirals. |Adenosine Monophosphate/analogs & derivatives/therapeutic use[MESH] |Alanine/analogs & derivatives/therapeutic use[MESH] |Amides/therapeutic use[MESH] |Antiviral Agents/*therapeutic use[MESH] |Betacoronavirus/*drug effects/immunology/pathogenicity[MESH] |COVID-19[MESH] |Coronavirus Infections/*drug therapy/immunology/mortality/virology[MESH] |Drug Administration Schedule[MESH] |Drug Combinations[MESH] |Drug Repositioning[MESH] |Humans[MESH] |Hydroxychloroquine/therapeutic use[MESH] |Interferons/*therapeutic use[MESH] |Lopinavir/*therapeutic use[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy/immunology/mortality/virology[MESH] |Pyrazines/therapeutic use[MESH] |Randomized Controlled Trials as Topic[MESH] |Ribavirin/*therapeutic use[MESH] |Ritonavir/*therapeutic use[MESH] |SARS-CoV-2[MESH] |Survival Analysis[MESH]Clinical Trials of Repurposed Antivirals for SARS-CoV-2 (epmc).pdf DeepDyve Pubget Overpricing